Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Second-line and Third-line therapy for Autoimmune Hepatitis A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Impaired cerebral microcirculation induced by ammonium chloride in rats is due to cortical adenosine release

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Micro-elimination - A path to global elimination of hepatitis C

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Reversal of Acute Liver Failure Due to Wilson Disease by a Regimen of High-Volume Plasma Exchange and Penicillamine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Risk markers for later cardiovascular diseases in liver-transplanted children and adolescents

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Ansgar W Lohse
  • Marcial Sebode
  • Marianne H Jørgensen
  • Henriette Ytting
  • Tom H Karlsen
  • Deirdre Kelly
  • Michael P Manns
  • Mette Vesterhus
  • European Reference Network on Hepatological Diseases (ERN RARE-LIVER) and of the International Autoimmune Hepatitis Group (IAIHG)
Vis graf over relationer

Autoimmune hepatitis in the majority of patients responds well to standard immunosuppressive therapy with steroids and azathioprine, and while untreated disease is usually fatal, patients responding well to therapy have an excellent prognosis. However, about 10-20% of patients present therapeutic challenges due to an insufficient response or intolerable side-effects to standard therapy, requiring dose-adaptation or switch of therapy. While there is a fairly good agreement on second-line treatment options, there is very wide variation in the indication and use of possible third-line therapies. The European Reference Network on Hepatological Diseases (ERN RARE-LIVER) and the International Autoimmune Hepatitis Group (IAIHG) here offer a treatment algorithm for both children and adults that should help to standardize treatment approaches, in order to improve patient care as well as to allow comparison of treatment results in scientific publications.

OriginalsprogEngelsk
TidsskriftJournal of Hepatology
Vol/bind73
Udgave nummer6
Sider (fra-til)1496-1506
Antal sider11
ISSN0168-8278
DOI
StatusUdgivet - dec. 2020

Bibliografisk note

Copyright © 2020. Published by Elsevier B.V.

ID: 60546067